Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
Abstract The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real‐world utilizat...
Saved in:
| Main Authors: | Daisuke Goto, Rahul Khairnar, Jean A. Yared, Candice Yong, Dorothy Romanus, Eberechukwu Onukwugha, Julia F. Slejko |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs
by: Wei Ni, et al.
Published: (2025-03-01) -
Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration
by: Shih Chang Hsueh, et al.
Published: (2025-06-01) -
New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
by: OM Votyakova
Published: (2017-10-01) -
Front‐line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real‐world setting: A multicenter retrospective study in China
by: Li Bao, et al.
Published: (2023-02-01) -
Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare
by: Macall Leslie Salewon, et al.
Published: (2024-12-01)